Regeneron Pharmaceuticals Profile



Odds of Distress

Check how we calculate scores
Equity ratings for Regeneron Pharmaceuticals are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting June 26, 2019 and ending today August 25, 2019. Click here to learn more.
USD 8.17  2.77%

Regeneron Pharmaceuticals Summary

Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,549 people. The company currently falls under 'Large-Cap' category with current market capitalization of 32.6B. Regeneron Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 107.73M outstanding shares of which 2.35M shares are at this time shorted by private and institutional investors with about 2.94 trading days to cover. REGENERON PHARMAC currently holds about 2.67B in cash with 1.12B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 24.4.
Check Regeneron Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Regeneron Pharmaceuticals Target Price Odds Analysis

Odds Below 286.85HorizonTargetOdds Above 286.85
1.48%30 days 286.85 98.48%
Based on normal probability distribution, the odds of Regeneron Pharmaceuticals to move above current price in 30 days from now is about 98.0% (This Regeneron Pharmaceuticals probability density function shows the probability of Regeneron Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Regeneron Pharmaceuticals Top Holders

Regeneron Pharmaceuticals Income Statement Over Time

Direct Expenses    Earning Before Interest and Taxes EBIT    Net Income    

Regeneron Pharmaceuticals Key Fundamentals

Regeneron Pharmaceuticals Against Markets

Regeneron Pharmaceuticals Vital Trading Data

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people. more
NameRegeneron Pharmaceuticals
President CEO, DirectorLeonard SchleiferView All
Thematic Classification
Currently Active Investing Idea
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock View All
RegionNorth America
Business Address777 Old Saw Mill River Road
Foreign Associates
ExchangeBATS Exchange
CIK Number0000872589
Phone914 847 7000
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterJune 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestJuly 31, 2019

Regeneron Pharmaceuticals Corporate Directors

Charles Baker Independent Director
Joseph Goldstein Independent Director
Anthony Coles Independent Director
Additionally take a look at Your Equity Center. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.